filmov
tv
Twist Bioscience, Cathie Wood's Latest Disaster
![preview_player](https://i.ytimg.com/vi/2q0UgEtfPwc/maxresdefault.jpg)
Показать описание
In today's video, we continue our exploration of the turbulent journey that is Cathie Wood's Ark Invest, focusing on one of their most troubled ETFs, ARKG Genomic Revolution ETF. Over the past 5 years, ARKG has underperformed the S&P 500 by a staggering 70%. We've previously delved into one of ARKG's holdings, Ginkgo Bioworks, and today we turn our attention to another key player, Twist Biosciences. Twist is a significant holding in the ARKG ETF, with Ark Invest being its largest shareholder, owning 12% of the company's outstanding shares.
Founded in 2013 and going public in 2018, Twist Biosciences promised to revolutionize synthetic biology with its gene editing microchip, claiming it could create synthetic genes thousands of times faster than traditional methods. This breakthrough was anticipated to accelerate drug discovery, develop hyperproductive plant strains to combat world hunger, and open doors to numerous other revolutionary applications. This excitement drove Twist's share price to nearly $200 in 2021, giving the company a valuation close to $10 billion. However, since then, Twist Biosciences' stock has plummeted by almost 90%, resulting in substantial losses for Ark's investors.
In this video, we take a deep dive into Twist Bioscience, exploring why investors were so enthusiastic about it just two years ago and dissecting the factors behind its catastrophic share price decline.
Nothing in this video is investing advice, we are giving our own opinions based on publicly available information.
0:00 - 1:26 Intro
1:27 - 5:55 What Twist Does
5:56 The Bear Case
#Wallstreetmillennial #syntheticbiology #cathiewood #arkinvest
––––––––––––––––––––––––––––––
Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0
––––––––––––––––––––––––––––––
Founded in 2013 and going public in 2018, Twist Biosciences promised to revolutionize synthetic biology with its gene editing microchip, claiming it could create synthetic genes thousands of times faster than traditional methods. This breakthrough was anticipated to accelerate drug discovery, develop hyperproductive plant strains to combat world hunger, and open doors to numerous other revolutionary applications. This excitement drove Twist's share price to nearly $200 in 2021, giving the company a valuation close to $10 billion. However, since then, Twist Biosciences' stock has plummeted by almost 90%, resulting in substantial losses for Ark's investors.
In this video, we take a deep dive into Twist Bioscience, exploring why investors were so enthusiastic about it just two years ago and dissecting the factors behind its catastrophic share price decline.
Nothing in this video is investing advice, we are giving our own opinions based on publicly available information.
0:00 - 1:26 Intro
1:27 - 5:55 What Twist Does
5:56 The Bear Case
#Wallstreetmillennial #syntheticbiology #cathiewood #arkinvest
––––––––––––––––––––––––––––––
Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0
––––––––––––––––––––––––––––––
Комментарии